# Siairan Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/siairan-medical

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou Industrial Park, China
- Total disclosed funding: $14M
- Latest round: Angel (Jun 1, 2023)
- Investors on record: 3

## About

Founded in 2022 and based in Suzhou, China, Siairan Medical is a medical research service provider dedicated to the development of precise, intelligent and minimally invasive ophthalmic devices. In 2023, the company closed an angel funding from new investors Apricot Capital and Tianhui Hongyou Investment Management, and Huatong Capital. In September 2024, it raised CNY 100 million in venture funding led by new investor Tsingstone Capital. In September 2025, Siairan Medical closed a venture funding co-led by new investors Cenova Ventures and Shunwei Capital Partners, with participation from returning investors HighLight Capital and Insight Capital. 

Siairan Medical focuses on providing precise, intelligent, minimally invasive surgical treatment solutions for ophthalmology. The company's R&D products include phacoemulsification and vitrectomy machines, vitrectomy accelerators, and disposable ophthalmic medical consumables' vitrectomy kits/surgical kits. The phaco-vitrectomy machine helps doctors perform various eye surgeries, such as cataract surgery and retinal surgery, through cutting, grinding and tissue processing technologies. Ophthalmic medical consumables include surgical blades, syringes, catheters, guide wires, etc., which are mainly used for ophthalmic surgical cutting, suturing, injection and guidance operations. 

The company generates revenue by providing ophthalmology with an all-in-one phacoemulsifier and its supporting consumables, digital surgical microscopes and other ophthalmic surgical instruments.

The funding raised in September 2025 will be primarily used to further develop the company's first independently developed phaco-vitrectomy product line, further enrich the company's ophthalmic surgical equipment portfolio, accelerate import substitution of domestically produced high-end ophthalmic instruments, and accelerate the company's overseas expansion.

## Funding rounds

- Angel, Jun 1, 2023, $14M — Apricot Capital, Tenykin Capital, Huatong Capital

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Angel
- Tenykin Capital (https://capitalatlas.ai/funds/tenykin-capital) — Angel
- Huatong Capital — Angel